Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.54 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.52 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.52 |
| ▸ | CFB | P00751 | 11/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.50 |
| ▸ | GSK3B | P49841 | 4/20 | 0.50 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15625905 | 0.87 | MAPK10 (0.44) | PIN1PKN1PKN2CFBCSNK1D | |
| SCHEMBL803692 | 0.84 | CSNK1D (0.59) | PIN1PKN1PKN2CFBCSNK1D | |
| SCHEMBL7655150 | 0.84 | ALDH1A1 (0.58) | PIN1PKN1PKN2CFBCSNK1D | |
| SCHEMBL1245514 | 0.78 | PIN1 (0.58) | PIN1PKN1PKN2CFBCSNK1D | |
| SCHEMBL20495149 | 0.77 | ABL1 (0.42) | CSNK1DCSNK1A1GSK3BCSNK1G2 | |
| SCHEMBL1358510 | 0.76 | ALDH1A1 (0.58) | METAP2METAP1 | |
| SCHEMBL1253278 | 0.76 | PKN1 (0.58) | PIN1PKN1PKN2CSNK1DCSNK1A1 | |
| SCHEMBL1793328 | 0.75 | PIN1 (0.58) | PIN1PKN1PKN2CFBCSNK1D | |
| SCHEMBL22219469 | 0.75 | PIN1 (0.58) | PIN1PKN1PKN2CFBCSNK1D | |
| SCHEMBL12430878 | 0.75 | CSNK1D (0.61) | PIN1PKN1PKN2CFBCSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-3860636-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | Disc Medicine, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| CN-112996529-A | Matriptase 2 inhibitor and application thereof | 迪斯克医药公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020072580-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | PIN1 402/4885PKN1 2423/4885PKN2 1554/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | PIN1 402/4885PKN1 2423/4885PKN2 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.